Climate change and tuberculosis: an analytical framework Climate change is likely to exacerbate a range of determinants that drive tuberculosis, the world's leading cause of death from a single infectious agent. However, tuberculosis is often neglected in w...

Our framework that informed the @who.int TB & climate change policy brief out now in @lancetrespirmed.bsky.social, exploring the intersections and implications of climate change for the TB epidemic. Key message? TB should be considered a climate-sensitive disease
www.thelancet.com/journals/lan...

Reflecting on this year’s #TB #UnionConf2024 and am so inspired by the brilliant minds and groundbreaking research being done to combat this global health threat. Special shoutout to the TB Modelling Group @lshtm.bsky.social 🫁

Our findings support the WHO's empirical BPaLM recommendation critical for settings with limited diagnostic access.

@cfmcquaid.bsky.social @gmknght.bsky.social @sedonasweeney.bsky.social @tb-lshtm.bsky.social @cmmid-lshtm.bsky.social @lshtm-tbmod.bsky.social @plos.org @plosglobalpublichealth.org

Impact of fluoroquinolone resistance on the cost-effectiveness of empiric treatment for multidrug- or rifampicin-resistant tuberculosis The WHO recommends the bedaquiline, pretomanid, and linezolid (BPaL) regimen with the additional fluoroquinolone antibiotic moxifloxacin (BPaLM) for initial treatment of multidrug- or rifampicin-resis...

When fluoroquinolone resistance status is unknown, empirical use of BPaLM (adding moxifloxacin to BPaL) is cost-effective as a replacement for BPaL even with high fluoroquinolone resistance levels! 🦠💊

doi.org/10.1371/jour...